Cello Health (CLL) Given Corporate Rating at FinnCap Posted by Shane Hupp on Mar 24th, 2019 Tweet

FinnCap restated their corporate rating on shares of Cello Health (LON:CLL) in a research note released on Thursday morning.

Cello Health stock opened at GBX 122.50 ($1.60) on Thursday. The company has a debt-to-equity ratio of 8.77, a quick ratio of 1.39 and a current ratio of 1.39. Cello Health has a 1 year low of GBX 95 ($1.24) and a 1 year high of GBX 139.88 ($1.83). The stock has a market capitalization of $128.27 million and a PE ratio of 29.17. Get Cello Health alerts:

The firm also recently declared a dividend, which will be paid on Friday, May 24th. Stockholders of record on Thursday, April 25th will be given a GBX 2.75 ($0.04) dividend. This is an increase from Cello Health’s previous dividend of $1.10. This represents a dividend yield of 2.24%. The ex-dividend date is Thursday, April 25th. Cello Health’s dividend payout ratio (DPR) is presently 0.95%. About Cello Health

Cello Health plc, together with its subsidiaries, provides marketing services in the United Kingdom, Rest of Europe, the United States, and internationally. It operates in two segments, Cello Health and Cello Signal. The Cello Health segment offers market research, consulting, and communications services principally to the pharmaceutical and healthcare clients.